Status:
COMPLETED
A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Eligibility:
MALE
20-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in Japanese healthy male subjects
Eligibility Criteria
Inclusion
- Healthy Japanese males aged ≥20 and ≤40 years of age
- Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to Hepatitis C virus
Exclusion
- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP
- History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00741689
Start Date
August 1 2008
End Date
December 1 2008
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Glendale, California, United States